FIELD: medicine.
SUBSTANCE: using a compound representing a bicyclic pyrimidine derivative as Hrf2 transcription factor activators.
EFFECT: compounds of general formula can be used preventively to increase body defences before operations with toxic chemicals and high radiation doses.
3 cl, 7 tbl, 11 ex, 9 dwg
Title | Year | Author | Number |
---|---|---|---|
AGENT POSSESSING ENDOTHELIUM PROTECTIVE ACTIVITY | 2014 |
|
RU2563622C1 |
EDARAVON COMBINATION FOR TREATING ISCHEMIC BRAIN INJURY | 2017 |
|
RU2693627C2 |
AGENT POSSESSING ANTIRADICAL, CEREBROPROTECTIVE AND ANTIISCHEMIC PROPERTIES | 2010 |
|
RU2445090C1 |
MEANS FOR TREATING ISCHEMIA OF VASCULAR BRAINS | 2016 |
|
RU2625740C1 |
NEUROPROTECTIVE MEANS, HAVING THE PROPERTIES OF ANTIOXIDANT AND NITRIC OXIDE DONATOR | 2016 |
|
RU2680526C1 |
AGENT WITH ANTI-STROKE ACTION | 2018 |
|
RU2675601C1 |
AGENT WITH ANTIAPOPTOTIC ACTIVITY | 2018 |
|
RU2685428C1 |
USE OF PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ALFOSCERATE AND 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE AS NEUROPROTECTIVE AGENT IN CEREBRAL ISCHEMIA | 2023 |
|
RU2819828C1 |
APPLICATION OF KAURAN COMPOUNDS FOR MEDICINES PRODUCTION | 2004 |
|
RU2345761C2 |
STEROIDAL NITRONES FOR TREATMENT AND PREVENTION OF CEREBRAL STROKE OR ISCHEMIA, ALZHEIMER'S AND PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS | 2014 |
|
RU2668514C2 |
Authors
Dates
2015-04-10—Published
2014-03-20—Filed